(I) Introduction
In eukaryotic cells, secreted and membrane proteins are frequently modified with complex glycan structures. The latter arise as a consequence of three distinct types of modifications: N-linked glycosylation of asparagine within the consensus sequence Asn-Xaa-Ser/Thr (Kornfeld and Kornfeld, 1985; Herscovics and Orlean, 1993; Orlean, 1996) , 0-linked glycosylation of serine or threonine (Tanner and Lehle, 1987; Hounsell et al., 1996) , and glycosylphosphatidyl inositol derivatization of the carboxyl-terminal carboxyl groups (Takeda and Kinoshita, 1995; Udenfriend and Kodukula, 1995) . The modification of proteins with N- linked glycans is of particular interest because N-glycosylation is essential for cell viability, it involves a multitude of enzymes, and at least half of the genes functioning in this biosynthetic pathway have been conserved through evolution. The most likely explanation for this essential function, the number of enzymatic reactions it entails, and their evolutionary conservation is that Nlinked carbohydrates play roles in diverse biological processes such as protein folding and conformation, stability, and targeting to subcellular and extracellular sites, as well as cell-matrix and cell-cell interactions (Varki, 1993; Fiedler and Simons, 1996) . In addition, most recent studies have revealed crucial roles for N-glycosylation in cell-cycle progression (Benton et al., 1996 ; Lennon et al., likely to be critical to the development and homeostasis of oral tissues, such as the major and minor salivary glands, the gingiva, and the oral mucosa. In addition, the modification of proteins with N-linked glycans may affect the onset and progression of oral pathologies. Since the components of the immune system, such as immunoglobulins and selectins, are N-glycoproteins, Nlinked glycans may function as potential regulators of oral immune responses, including mucosal immunity. Moreover, many N-glycoproteins, such as lactoferrin, participate directly in non-immune oral defenses. Because N-glycoproteins are increasingly recognized as potential therapeutic agents for disease control, the understanding of the molecular details of N-glycoprotein biosynthesis may prove critical to the gaining of further insights into the underlying causes of, and the design of rational therapeutic approaches for, oral dysfunctions.
The reactions of the protein N-glycosylation pathway occur along the secretory pathway and entail many enzymes localized in the endoplasmic reticulum (ER) and the Golgi. The biochemistry of N-glycosylation, including the synthesis of lipid-linked oligosaccharide precursor and the subsequent processing events in the ER and the Golgi, has been elucidated for some time. Since then, many of the genes encoding the ER and Golgi glycosyltransferases and glycosidases have been isolated and characterized from a variety of sources (Table) . Increasingly, transgenic and gene disruption techniques are utilized for the identification of their functions. Based on these studies, it has been recognized that N-glycosylation influences the conformational dynamics of nascent polypeptides and that, in some cases, it confers their biological activity. There still remains an apparent paradox that although N-glycosylation is indispensable to cell viability, many N-glycoproteins remain functional regardless of their glycosylation status. In other words, the consequences of altering the spectrum of carbohydrates expressed by a cell or an organism range from none to death. The speed with which new information in the field of glycobiology is revealed, however, will soon lead to the identification of the downstream genetic targets that are critical for viability.
The initial steps involving the synthesis of lipidlinked oligosaccharide precursor and the removal of the three glucose residues are identical in all eukaryotes. Indeed, pioneering studies with yeast offered a combination of genetics and molecular approaches through which breakthrough discoveries about the molecular details of N-glycosylation were first obtained. Specifically, yeast provided mutants and the ease of genetic manipulation which at that time were not easily accessible in mammalian somatic cells. Moreover, with the completion of the cloning of the yeast genome in 1996, additional homologies among the N-glycosylation genes from distinct biological systems were uncovered, even when the enzymes they encode have diverged functionally in evolution.
During the past two decades, numerous reviews regarding protein N-glycosylation have been published (Hubbard and Ivatt, 1981; Kornfeld and Kornfeld, 1985; Herscovics and Orlean, 1993; Daniel et al., 1994; Moremen et al., 1994; Colley, 1997) . Perhaps the most exciting new insights regarding N-glycosylation have emerged recently in relation to its component genes and their involvement in such processes as morphogenesis, proliferation, differentiation, and apoptosis. Therefore, while this review provides a summary of the biochemistry of N-glycosylation, it focuses on the component genes, their characteristics and functions. Furthermore, information will be presented regarding gene homologies and corresponding mutant phenotypes from different biological systems ranging from yeast to mammals.
(11) Protein N-glycosylation ( 
1) YEAST AS A MODEL BIOLOGICAL SYSTEM FOR THE STUDY OF N-GLYCOSYLATION
Early studies with the yeast Saccharomyces cerevisiae provided invaluable insight into the structure and function of enzymes involved in N-glycosylation. As a microbe and lower eukaryote, yeast offers ease of handling and the use of diverse strategies for mutant selection, as well as cloning, characterization, and manipulation of genes. Several different strategies have been used to isolate yeast N-glycosylation mutants. One strategy, the 12-3HI mannose suicide selection (Huffaker and Robbins, 1983) , involved screening for mutants bearing temperature-sensitive defects in N-glycosylation. The rationale was based on the fact that mutagenized yeast cells which survive radiation damage do so by virtue of incorporating a lesser quantity of radioactive mannose. This allowed for the isolation of viable mutant strains (alg mutants) with defects in essential as well as non-essential genes of the dolichol pathway. Another successful selection procedure involved the screening of mutagenized cells with antibodies to cell wall carbohydrates so that those with aberrant surface glycans can be identified. The latter led to the isolation of mutants (mnn) with defects in N-linked glycan maturation steps. Importantly, screens for mutants with defects in such functions as secretion (sec mutants), ATP metabolism (van/vrg mutants), and sensitivity to the aminoglycoside, hygromycin B, have also led to the identification of mutant alleles defective in N-glycosylation (Schekman et al., 1983; Ballou, 1990; Ballou et al., 1991; Roos et al., 1994; Dean, 1995; Kanik-Ennulat et al., 1995) . These important studies highlighted the interaction of N-glycosylation with secretion and organization of the endomembrane system. The most recent screens of yeast mutants for new complementation groups and synthetic lethal effects have pointed to rather unexpected relationships between the early N-glycosylation genes and Gl cyclins, as well as calmodulin (Benton et al., 1996; Lennon et al., 1997b; Ohya and Botstein, 1994) .
Much of gene cloning in yeast has been based on the isolation of genes by complementation of mutant phenotypes by means of yeast genomic libraries. Alternatively, genes can be isolated through screens of multicopy suppression of mutant phenotypes. Characterization of the cloned genes has been facilitated by the fact that few yeast genes contain introns. When mutants are not available, genes can be isolated by overexpression on high-copy plasmids followed by screens for increased function. Another strategy involves the isolation of genes conferring either increased resistance or hypersensitivity to a toxic agent. The former gene dosage approach was used to isolate the first N-glycosylation gene, ALG7, by the selection of viable cells, transformed with multicopy plasmids containing fragments of the yeast genomic library, in the presence of tunicamycin, a specific inhibitor of its gene product (Rine et al., 1983) . Later, a similar approach was used to isolate the mammalian homologue of ALG7. Last, in contrast to higher eukaryotes, normal yeast genes can be easily replaced with their mutant alleles, and the consequence of such a replacement on cellular function can be readily observed (Rothstein, 1983 In all eukaryotes, biosynthesis of N-glycoproteins is initiated with the dolichol pathway in the endoplasmic reticulum (Kornfeld and Kornfeld, 1985; Herscovics and Orlean, 1993) . The biosynthesis of the lipid-linked oligosaccharide is highly conserved between yeast and mammals. The precursor oligosaccharide GIcNAc2Man9Glc3 is assembled on the polyisoprenol carrier lipid, Dol-PP, through a stepwise addition of monosaccharides in a series of reactions catalyzed by glycosyltransferases (Fig., A) . All ER glycosyltransferases are transmembrane proteins. The first seven sugars are transferred from the sugar nucleotides UDP-GlcNAc and GDP-Man at the cytosolic side of the ER. Evidence suggests that the heptasaccharide is then translocated to the lumen of the ER, the subsequent reactions entailing the transfer of four mannose residues from Dol-P-Man and three glucose moieties from Dol-P-Glc.
(i) Mutants in the dolichol pathway Much of the dissection of events in the dolichol pathway has been aided by the availability of mutants. Cells with increased resistance to tunicamycin, due to the amplification of the first dolichol pathway gene, ALG7, have been selected both in yeast (Rine et al., 1983) and in CHO cells (Scocca and Krag, 1990) . Nonetheless, to date, the majority of mutants blocked in the ER reactions have been obtained from yeast. Mutants accumulating mainly Dol-PP-GlcNAc2 (algl), Dol-PP-GlcNAc2Man2 (alg2), Dol-PP-GlcNAc2Man5 (alg3), Dol-PP-GlcNAc2Man6 (alg9), Dol-PP-GlcNAc2Man9 (alg5 and alg6), and Dol-PPGlcNAc2Man9Glc (alg8) have been selected by means of a suicide selection procedure with 3H-GlcN or 3H-Man (Huffaker and Robbins, 1983) . These mutants proved extremely useful for ordering the steps in the pathway based on epistatic relationships both between and among them, as well as for cloning the corresponding genes. Moreover, the phenotypes of the yeast mutants revealed that the early steps in the pathway were essential for viability. Thus, algl and alg2 mutants, as well as alg4/sec53, are blocked at steps indispensable for growth, while alg3, alg9, alg5, dpgl, alg6, and alg8 mutants display no obvious phenotypes. Since alg3 structures can be transferred to protein and then elongated by the processing transferases, the feasibility of processing (or elongation) of the core structures appears to represent the viability requirement.
(ii) Transferase reactions The first step in the pathway involves the addition of the initial N-acetylglucosamine to the dolichol carrier in the membrane of the ER (Fig., A) . This reaction is catalyzed by the dolichol-P-dependent N-acetylglucosamine-l-Ptransferase (GPT), encoded by the ALG7 gene (Table) . ALG7 was first isolated by the selection of transformants resistant to the inhibitor of GPT, tunicamycin (Rine et al., 1983; Barnes et al., 1984) . Both in yeast and in mammals, ALG7 has a complex transcription pattern, producing multiple mRNAs with different lengths of the 3' untranslated region (3 UTR) (Kukuruzinska and Robbins, 1987; Scocca and Krag, 1990; Rajput et al., 1994a; Huang et al., 1998) . Additional ALG7 5 transcript heterogeneity has been observed in CHO cells (Huang et al., 1998) . The yeast GPT is a 48-kDa protein with two potential N-glycosylation sites. The murine GPT is a 48-kDa protein, while the hamster species, despite the predicted 48-kDa size, displays a much smaller molecular weight that may result from the utilization of an in-frame AUG downstream from the first (Huang et al., 1998) . Following ALG7, several ALG genes function sequentially in a stepwise addition of monosaccharides to produce a 14-residue, mature oligosaccharide precursor (Fig., A; Table) . The ALG I and ALG2 genes were cloned by complementation of temperature-sensitive phenotypes of algI and alg2 mutants, respectively. ALGI encodes 3-1,4-mannosyltransferase, which functions in the transfer of mannose from GDP-Man to Dol-PP-GIcNAc2 (Couto et al., 1984) . ALG I also has a complex transcription pattern, although the differences reside in the 5' UTR (Albright Kilker et al., 1981; Hettkamp etal., 1 984; Bause et al., 1986 Bause et al., , 1989 Szumilo et al., 1986; Shailubhai et al., 1987; Tillman et al., 1987; Tulsiani et al., 1990; Kalz-Fuller et al., 1995; Khan etal., 1997 Brada & Dubach, 1984 Hettkamp et al., 1984; Saxena et al., 1987; Kaushal et al., 1 990a; Tulsiani et al., 1990; Trombetta et al., 1996; Arendt and Ostergaard, 1997 Glucosidase ll murine, bovine, human ;al a-fucosyltransferase, a-i1,3-fucosyltransferase/membrane Larsen et al., 1990; Plau eta!., 1994;  Hitoshi et a/.,1 995, Masutani & Kimura, 1995; Rouquier et al., 1995; Cohney et al., 1996; Hitoshi et al., 1996; West eta!., 1996 Muramatsu et al., 1986 Goelz et al., 1990; Foster et al., 1991; Kumar et al., 1991; Lowe et al., 1991; Koszdin & Bowen, 1992; Weston eta!., 1992a,b; Natsuka et al., 1994; Sasaki et al., 1994; Cameron et al., 1995; Johnson et al., 1995; Staudacher et al., 1995; Lee et al., 1996; Ozawa & Muramatsu, 1996 and Robbins, 1990) . ALG2 encodes an ut-1,3-mannosyltransferase catalyzing the mannosylation of Dol-PPGlcNAc2Man2 (Jackson et al., 1993) . Only a single transcript is produced from the ALG2 gene (Jackson et al., 1993; Kukuruzinska and Lennon, 1994) .
The lack of obvious phenotypes of mutants bearing defects in the later steps in the dolichol pathway has necessitated the use of synthetic mutations to isolate the corresponding genes. Thus, non-conditional alg mutants are impaired in growth at 300C when crossed with temperature-sensitive w6bpl mutants. The latter mutant is defective in the transfer of oligosaccharide to protein. In this way, ALG6 and ALG8 genes were cloned by complementation of growth-defective phenotype (Stagljar et al., 1994; Reiss et al., 1996) . The ALG6 and ALG8 genes encode potential glucosyltransferases which transfer the first and second o-1,3-glucoses to Dol-PPGlcNAc2Manq, with each transferase displaying acceptor specificity. ALG8 produces a single transcript of 2.1 kb, whereas two mRNAs, 1.6 and 1.8 kb, are transcribed from ALG6 . Additional mutants, generated by screens for synthetic lethality by crosses with wbp 1, include alg9 and algIO, which accumulate Dol-PPGlcNAc2Man6 and Dol-PP-GlcNAc2Man9Glc2, respectively. ALG9 has not yet been fully characterized (Burda et al. 1996) . Another synthetic phenotype was obtained from a cross of alg3 with stt3, a mutation that affects the transfer of the oligosaccharide to the protein. The (Pathaket al., 1995) , OST2 (Silberstein etal., 1995b) , OST3 (Karaoglu et al., 1995a) , OST4 (Chi et al., 1996) , OST5 (Reiss et al., 1997) , STT3 (Zufferey et al., 1995) , and MEGI (Roos et al., 1997 (Kelleher and Gilmore, 1994; Knauer and Lehle, 1994) . Interestingly, Swplp displays homology with mammalian ribophorin 11 (Kelleher and Gilmore, 1994) . Other genes encoding OT subunits, OSTI, OST2, and OST3, were cloned by sequence homology to the components of the purified OT complex. Ostlp is homologous to mammalian ribophorin I (Silberstein et al., 1995a ).
Similar to SWPI, multicopy expression of OST2 can suppress wbpl mutations. Ost2p has sequence homology to DAD1 protein (defender against apoptotic death) (Silberstein and Gilmore, 1996) . Although OST3 is a non-essential gene, mutants with disruption in this gene display "biased underglycosylation", where soluble glycoproteins that use the signal recognition particle (SRP)-independent pathway are glycosylated normally, while membrane glycoproteins, synthesized via the SRPdependent pathway, are underglycosylated. Thus, Ost3p may be involved in the positioning of the OT complex for the SRP-dependent pathway. Another, small, 9-kDa, subunit of the OT complex is encoded by the OST5 gene. The latter was cloned by complementation of the synthetic phenotype of the ost5 mutation with alg5 (Reiss et al., 1997 Table: GIs 1, 11x, are ox-glucosidases 1, lot, and Ill, respectively; Endo a-man, endo cx-mannosidase; ER ot-man 1, 11 are endoplasmic reticulum ot-mannosidases and 11; Man9-man, mannose9-specific cx-mannosidase; Golgi (x-man 1, 11, III are Golgi a-mannosidases 1, 11, and III; (x-1 ,2/1,3/1,6-man, x-1,2/1,3/ 1,6-mannosidase; G cNAc-TI-V, N-acetylglucosaminyltransferases I-V; a-FTs, oL-fucosyltransferases; D3-Gal-T, D3-galactosyltransferase; a-NANA-Ts, ot-sialyltransferases.
oligosaccharide precursor is Ost4p, a small, 3.9-kDa, hydrophobic membrane protein. Mutations in OST4 were isolated with screens for defects in the oligosaccharide transfer to a peptide acceptor, as well as for resistance to orthovanadate (Roos et al., 1994; Chi et al., 1996) . The latter phenotype is typically associated with defects in the secretory pathway at the Golgi level and with defects related to ATP metabolism. ost4 mutants are impaired in growth at 25°C, but are inviable at 37°C, and show an attenuated transfer of the oligosaccharide in vivo. The ost4 mutants are suppressed by a multicopy expression of MEGO (Roos et al., 1994; Chi et al., 1996) , although the nature of the latter gene is obscure. The function of OST4 may involve either stabilization or assembly of the OT complex (Reiss et al., 1997 pletely, with the Asn-Xaa-Thr sites being preferential acceptors to Asn-Xaa-Ser (Gavel and Von Heijne, 1990 ). Moreover, secondary structure also influences the in vivo efficiency of N-glycosylation, and sites located less than 12-14 residues from a transmembrane segment of a protein are typically not modified. Also, sites close to the Cterminus of a protein are not derivatized as effectively. The completed oligosaccharide precursor is the preferred donor for OT in most eukaryotes. Studies with the yeast alg mutants, as well as with porcine OT, showed that incomplete dolichol-oligosaccharides can be transferred by the enzyme in vivo and in vitro, although at a slower rate (Silberstein and Gilmore, 1996) .
(iv) Processing of the oligosaccharides in the ER The transfer of the precursor oligosaccharide to protein in yeast is followed by a series of trimming reactions involving glucosidases I and 11 as well as cx-mannosidase (Fig., B) . The terminal cx-1,2-glucose is removed by glucosidase I (Kilker et al., 1981; Bause et al., 1986; Tillman et al., 1987) , and the two ax-1,3-glucoses are removed by glucosidase 11 (Saunier et al., 1982; Trombetta et al., 1996) . The removal of glucose is not necessary for further extension in yeast, since the glsl mutant, which retains all three glucose residues, grows and extends the outer chains normally (Esmon et al., 1984) . Following the removal of glucose, a single, specific (x-1,2-mannose residue is cleaved off, leaving a single isomer structure GIcNAc2Man, (Byrd et al., 1982) . The gene encoding the mannosidase, MNSI, has been cloned (Camirand et al., 1991) , the enzyme purified (Jelenik-Kelly and Herscovics, 1988) , and shown to be neither essential for growth nor required for outer chain extension (Puccia et al., 1993) . This mannosidase is Ca2+-dependent and inhibited by 1-deoxynojirimycin (dNI); it displays homology with mammalian Ca +-dependent (c-1,2-mannosidases, pointing to evolutionary conservation .
Similar to yeast, in mammalian cells, the trimming reactions in the ER involve the removal of the three glucoses and one mannose via the action of ct-glucosidases and 11 and an cx-1,2-mannosidase (Fig., C) . The cx-glucosidase enzyme has been purified from calf (Hettkamp et al, 1984) , rat (Tulsiani et al., 1990) , and porcine liver, lactating bovine mammary gland , mung bean seedlings (Szumilo et a., 1986) , and yeast (Kilker et al., 1981; Bause et al., 1986; Tillman et al, 1987) . Recently, cDNA clones for human glucosidase I were isolated (Kalz-Fuller et al., 1995) .
Localized in the ER, the mammalian enzyme is a tetramer composed of 85-92-kDa subunits, while the yeast protein has a subunit weight of 95 kDa (Table) . The x-1,2-glucosidase is inhibited by dNl and castanospermine, among others. Treatment of cells with either inhibitor prevents maturation of N-linked glycans and interferes with secretion and localization of some glycoproteins. Nonetheless, due to alternative pathways for the maturation of the oligosaccharide, the formation of complex structures is never completely inhibited by ct-1,2-glucosidase I inhibitors. One pathway involves the transfer of non-glucosylated oligosaccharide to protein, a predominant pathway in trypanosomes (Parodi, 1993) and in yeast mutants blocked in glucosyltransferase (Herscovics and Orlean, 1993) steps. In addition, another alternate pathway involves a Golgi endomannosidase which can cleave GlcNAc2Man9Glc1 3 to GIcNAc2Man8, by acting on oligosaccharides that have not been completely trimmed by glucosidases I and 11 in the ER . The latter endomannosidase is the only endoglycosidase so far identified in the N-glycosylation pathway.
ox-Glucosidase II has been purified from rat (Tulsiani et al., 1990) and calf (Hettkamp et al., 1984) liver, bovine mammary gland (Saxena et al., 1987) , porcine hepatocytes (Brada and Dubach, 1984) , mung bean seedlings (Kaushal et al., 1990a) , and yeast (Trombetta et al., 1996) . Murine oxglucosidase II cDNAs were recently cloned (Arendt and Ostergaard, 1997). The enzyme displays a subunit weight of 110-123 kDa, and it is inhibited with dNl and castanospermine . In porcine hepatocytes, it is localized to rough ER, smooth ER, and nuclear envelope, while in porcine kidney epithelial cells, it has also been detected in the Golgi and endocytic elements associated with the brush border (Lucocq et al., 1986) . The human ox-1,2-glucosidase 11 gene has been mapped to chromosome It (Martiniuk et al., 1985) .
Two mammalian glucosidase mutant cell lines have been isolated. Lec23 is a recessive mutant Chinese hamster ovary (CHO) cell line highly resistant to L-PHA that lacks ox-glucosidase I activity Lal et al., 1994) . These mutant cells synthesize, in addition to the complex structures, high mannose and hybrid N-glycans. The presence of complex glycans indicates the use of the endo ox-mannosidase alternative processing pathway.
(a) N-glycosylation and protein folding
In some eukaryotes, a monitoring system has been identified that assists in glycoprotein folding in the ER. Typically, unfolded and misfolded proteins are retained in the ER until they attain their native conformation (Herbert et al., 1995 (Fernandez et al., 1996) . This gene, gpt I', is not essential, and its disruption does not affect growth rates, although it does lead to smaller cell size. Nonetheless, gptl+ mRNA is induced in response to heat shock, inhibition of N-glycosylation, and conditions leading to protein misfolding in the ER (Fernandez et al., 1996) . In addition to calnexin, molecular chaperones that function in the proper folding of ER N-glycoproteins include calreticulin and the binding protein, BiB. Calnexin, calreticulin, and BiP have been conserved throughout evolution, from yeast to mammals, and shown to function in quality control in the ER (Herbert et al., 1995) .
(b) Retention of proteins in the ER Resident soluble ER proteins and some transmembrane type 11 proteins contain a C-terminal sorting signal, a tetrapeptide Lys/His-Asp-Glu-Leu. This tetrapeptide has been shown to be both sufficient and necessary for retention in the ER (Pelham, 1990) . The mechanism of retention most likely involves a continuous retrieval of proteins from a post-ER compartment, and utilizes a membrane-bound receptor in the Golgi that binds to these proteins and then enters a retrograde transport to deliver them to the ER. Thus, many ER proteins contain N-linked glycans typical of the Golgi modifications. The Lys/His-Asp-Glu-Leu receptor has been identified genetically first in yeast as encoded by the ERD2 gene, and later its homologs were discovered in many species, including humans (Lewis and Pelham, 1992) . The recycling of the receptor has been shown to be essential for growth in yeast (Townsley and Pelham, 1994) .
(3) REACTIONS IN THE GOLGI: SYNTHESIS OF MATURE N-LINKED GLYCAN STRUCTURES
The processing steps in the Golgi cisternae generate mature N-linked oligosaccharide structures. In contrast to reactions of the dolichol pathway, which are highly conserved in eukaryotes, the mature oligosaccharides differ quite significantly across the species (Fig., B, C) . The oligosaccharide chains of mature yeast N-linked glycoproteins either consist of a high-mannose "mature core" of 9-13 mannose residues, or they may contain extended branched mannan outer chains consisting of up to 200 residues (Ballou, 1990; Trimble and Atkinson, 1992) . The types of mature N-linked oligosaccharides synthesized in higher eukaryotes are significantly different from those found in yeast, and they predominantly involve high-mannose, complex, and mixed types of structures (Kornfeld and Kornfeld, 1985) .
(i) Synthesis of mature oligosaccharides in yeast The different mature carbohydrate structures produced in yeast are attained depending on the glycoprotein and on the individual N-linked sites within it. Local peptide conformation typically determines the accessibility to the transferases. The chains that are not extended are resistant to the deglycosylating enzyme endo-1-Nacetylglucosaminidase H (Trimble et al., 1983; Zeigler et al., 1988; Basco et al., 1993) .
Outer chain synthesis is initiated by the OCH 1 gene, encoding a-1,6-mannosyltransferase (Nakayama et al., 1992; Lehle et al., 1995) . OCH1 was cloned by complementation of the temperature-sensitive ochl phenotype (Nakayama et al., 1992) . OchIp is a transmembrane type II protein, localized in early Golgi (Chapman and Munro, 1994; Gaynor et al., 1994) , although it may be initially retrieved from the trans-Golgi (Harris and Waters, 1996) . OCH1 is a non-essential gene: Cells with a disruption in the gene are viable, and they lack u-1,6-polymannose outer chains. Nonetheless, these mutants are temperature-sensitive, indicating that the outer chains are needed for growth at higher temperatures. OCH 1 appears to extend the incomplete oligosaccharides in alg3 mutants and those blocked at the later steps, but not in algI and alg2 mutants, suggesting that this lack of extension may be responsible for the latter mutants' lethal phenotype.
In the formation of the "mature core" structures, addition of outer-chain ox-1,2-mannose may serve as a signal to prevent the extension of outer mannose chains (Ballou, 1990 ). An enzyme catalyzing the addition of cx-1,2-mannose, M2mt-lp, has been purified (Lewis and Ballou, 1991 (Yip et al., 1994) . Interestingly, this Mnnlp is mislocalized to the plasma membrane in clathrin-deficient strains (Lussier et al., 1996) , KTR2 (Lussier et al., 1993) , KTR3 (Bussereau et al., 1993) , KTR4 (Mallet et al., 1994) , KTR5, KTR6, and KTR7 . All these genes encode type II transmembrane proteins, with short N-terminal cytosolic tails and conserved luminal domains . Localized in the Golgi, Ktr I p, Ktr2p, and Yur I p display mannosyltransferase activities in vitro, and cells with disruptions in the genes that encode them are resistant to Kl killer toxin (Lussier et al., 1996) . The current understanding is that these enzymes constitute redundant mannosyltransferases (Lussier et al., 1996) .
Perturbations in Golgi N-glycosylation correlate with, and may result from, other malfunctions of the Golgi pathway. Several mutants, mnn7/8, mnn9, and mnn 10, were among the mutants isolated in a screen for sodium orthovanadate resistance and hygromycin B sensitivity (Ballou et al., 1991; Kanik-Ennulat et al., 1995) . The degree of vanadate resistance and hygromycin B sensitivity correlated with the severity of N-glycosylation defect (Dean, 1995; Kanik-Ennulatetal., 1995) . Since vanadate inhibits ATP metabolism, the resistance to this drug may reflect defects in the endomembrane system that prevent the access of the molecule to the Golgi lumen (Ballou et al., 1991) . Increased sensitivity to an aminoglycoside, hygromycin B, of the outer chain N-glycosylation mutants may reflect either enhanced uptake of this drug or inability to detoxify it. This discovery is of potential interest in therapeutics, since aminoglycosides are important anti-viral agents. In addition, mutants in the essential gene VRG4/VAN2, which functions in protein sorting in the Golgi and in retrieval of Lys/His-Asp-Glu-Lys-bearing proteins from the Golgi to the ER, show severe underglycosylation. These mutants are also orthovanadate-resistant . Mutants in non-essential ERDI gene are defective in the retention of the ER proteins and show underglycosylation (Hardwick et al., 1990) , while mutants in nonessential PMR1, a Golgi-localized Ca2+ ATPase, are blocked at the elongation of N-linked outer chains (Rudolph et al., 1989; Antebi and Fink, 1992; Sorin et al., 1997) . The latter phenotype is interesting, because it indicates that Ca2+ metabolism affects N-glycosylation. Additional functions to correlate with N-glycosylation are cell proliferation and polarization: mnnlO mutants display synthetic lethality with overproduction of mitotic cyclins, and are not able to target secretory vesicles effectively, most likely a consequence of perturbations in cytoskeletal re-arrangements needed for vesicle transport (Mondesert and Reed, 1996) . Last, a mutant in the dolichol pathway, alg2, has been shown to be allelic to a calmodulin mutant (Ohya, personal communication) . These studies support interrelationships among N-glycosylation, secretion, cytoskeletal organization, and cell proliferation.
(iii) Maturation of N-linked oligosaccharides in higher eukaryotes The structures of cellular oligosaccharides in higher eukaryotes are determined by a series of processing reactions, catalyzed by glycosyltransferases and glycosidases, that are initiated in the ER and then continued in the Golgi compartments (Fig., C) . N-linked glycan processing in higher eukaryotes is identical to that in yeast up to the removal of glucose residues with glucosidases I and II While the removal of mannose in yeast is restricted to a single a--1,2-mannose from the central arm of the oligosaccharide, it can entail the action of several mannosidases in higher eukaryotes.
Following the addition of the oligosaccharide to the protein, the maturation of glycans can proceed via different routes to generate distinct structures: high-mannose, hybrid, and complex oligosaccharides. Lysosomal enzymes are phosphorylated at this point by the initial transfer of GlcNAc-l-P to the C6 position of one or two mannose residues, and the Man-6-P terminus is uncapped by the removal of GlcNAc. In some cases, glycoproteins may retain their complete oligomannosidictype structure, or its incomplete variants, following the action of c,-mannosidases. Typically, however, all four Man residues are removed, leading to the formation of either complex-or hybrid-type chains. An alternative pathway utilizes the Golgi endo cx-mannosidase, which most likely acts on oligosaccharides that have escaped the ER, either due to incomplete action of glucosidase 11 or due to re-glucosylation in the ER. Found in many mammalian cells, this activity has not been detected in CHO cells (Hiraizumi et al., 1993) . Endo ax-mannosidase activity is inhibited by Glc ac-I,3-(l-deoxy)-mannojirimycin (dMNJ). When the latter inhibitor is used in conjunction with dNI, or with glucosidase-Il-deficient cells, no complex-type N-glycans are synthesized.
Additional trimming reactions entail further removal of three x-1 ,2-mannoses in the Golgi to generate a structure GlcNAc2Man . The removal of up to two mannose residues can also take place on glucosylated oligosaccharides. Mammalian cells express several processing cx-1,2-mannosidases with different subcellular locations and specificities (Table) . A Golgi ax-mannosidase activity has been found that can trim GlcNAc2Man6-9 to GlcNAc2Man 5. Based on in vivo studies with the mannosidase inhibitor, dMNI, there may be two, and possibly three, ot-mannosidase activities in the ER of mammalian cells (Bischoff et al., 1986 (11998) homologies, two distinct classes of c-mannosidases have been described (Daniel et al., 1994; Moremen et al., 1994) . One class includes evolutionarily conserved xmannosidases, found in both yeast and mammals. These enzymes, of 63-73-kDa subunit size, localize to both the ER and Golgi. This class of enzymes involves Golgi omannosidase IA and IB and Ca2+-dependent cu-1,2-mannosidases that include the yeast-specific (Man9)ER cx-1,2-mannosidase and the mammalian cx-1,2-mannosidases . The rat liver Golgi mannosidase IA is a tetramer of 57-58-kDa glycosylated subunits (Tabas and Kornfeld, 1979; Tulsiani et al., 1982; Lal et al., 1994) . Both mannosidase IA and IB are inhibited by dMNI, and they share antigenic determinants.
Ca2+-dependent ot-1,2-mannosidases belong to a multigene family. In yeast, this enzyme is Ca2+-dependent, inhibited by dMNJ and localized to the ER. The gene was isolated and predicted to encode a 63-kDa protein (Camirand et al., 1991) , close to the purified size of 67 kDa (Jelinek-Kelly and Herscovics, 1988; Zeigler and Trimble, 1991) . The enzyme belongs to type II transmembrane proteins and has three N-linked glycosylation sites, a Ca2+-binding consensus sequence, and a noncleavable signal sequence that serves as a transmembrane domain (Camirand et al., 1991) . The derived amino acid sequence has 36% identity and 58% similarity to the rabbit, mouse, and human cDNAs (Bause et al., 1993; Lal et al., 1994) that encode mannosidases of different specificities. It has no significant homology to the mammalian Ca2+-independent ER/cytosolic co-mannosidase . The mammalian Ca2+-dependent ox-1,2 mannosidase, a 52-kDa protein, is inhibited by dMNJ but not by swainsonine. In contrast to the yeast enzyme, the rabbit and rat liver proteins cleave GlcNA2Man9 to GlcNA2Man5 (Lal et al., 1994) . The cDNA sequence from the mouse predicts a 73-kDa type II transmembrane protein. Localized to the Golgi, this enzyme cross-reacts with the Golgi x-1,2-mannosidase IA (Lal et al., 1994) . The enzymes have also been isolated from calf (Bause et al., 1993) and porcine liver and have been shown to correspond to the protein encoded by the human cDNA (Bause et al., 1993) . The human cDNA predicts a protein of 71 kDa, 88% identical to the murine enzyme, and 35% identical to the yeast processing o-1,2-mannosidase. Hence, the rabbit, mouse, pig, calf, and human proteins are all species-specific variants of the same enzyme, antigenically related to rat liver ox-mannosidases IA and IB. Moreover, the high degree of identity to the yeast enzyme indicates that it has been conserved through evolution ). An additional mouse clone displaying 64% identity to the cDNA clone described above, 37% identity to the yeast ER c-1,2-mannosidase, and containing a Ca2+ consensus sequence has been isolated by means of sequences homologous to yeast and rabbit enzymes Lal et al., 1994) . Southern analyses revealed that these two mouse enzymes are produced by different genes, indicating that the ot-1,2-mannosidases belong to at least two gene families. Comparison of the two mouse cDNAs indicates that they encode enzymes, localized to the Golgi complex, with similar transmembrane domains but different cytosolic N-terminal sequences. The transcripts produced by the a-mannosidase genes are heterogeneous in size, ranging from 4.2 to 8.5 kb, suggesting a complex pattern of gene regulation .
The second class of mammalian mannosidases is more heterogeneous and includes Golgi a-mannosidase 11, tysosomal acidic x-mannosidase, and the mammalian cytosolic/ER a-mannosidase. These enzymes have subunit weights of 107-136 kDa and are partially inhibited by swainsonine. In spite of their varied localization and function, they display sequence homology. The Golgi utmannnosidase 11 removes only ox-1,3-and ox-1,6-linked mannoses from GlcNAc2Man 5GlcNAc to produce GlcNAc2Man3GlcNAc, and it requires a prior addition of the GlcNAc residue by GlcNAc transferase I (see below). The enzyme has been purified to homogeneity from rat liver and brain (Tulsiani et al., 1982; Moremen, 1989) and mung bean seedlings (Kaushal et al., 1990b) ; it is a transmembrane dimer of identical subunits of 132-kDa molecular weight. Golgi cx-mannosidase 11 is inhibited by swainsonine (Tulsiani et al., 1982) and mannostatin (Tropea et al., 1990) . The murine cDNA, isolated from the 3T3 cells, also predicts a transmembrane type II protein, with a cytosolic domain consisting of only five amino acids (Moremen and Robbins, 1991) . Although ce-mannosidase II is known to be localized to the Golgi, its precise localization within the Golgi complex appears to vary depending on the cell type. In some cases, the enzyme has also been detected on the surfaces of intestinal epithelial and pancreatic exocrine cells (Velasco et al., 1993) . Although this enzyme has been found in all mammalian tissues, its level is particularly low in the brain, most likely due to an alternative hydrolytic enzyme utilized in that tissue (Wilkerson and Touster, 1993) . As indicated below, however, an alternative hydrolytic enzyme is utilized in the brain. The human cx-mannosidase II cDNA, closely related to the murine species, has been mapped to chromosome V (Moremen and Robbins, 1991) . Interestingly, the catalytic domain of the murine enzyme exhibits a high degree of homology to a lysosomal cxmannosidase from Dictyostelium discoideum (Schatzle et al., 1992) . This suggests a common origin of the two enzymes from an ancestral gene which underwent duplication and divergence. Some degree of sequence homology between the catalytic domain of murine ax-mannosidase II and the rat cytosolic/ER ox-mannosidase as well as the yeast vacuolar enzyme has been detected . Another mannosidase that belongs to class 2 of a-mannosidases is the ER/cytosolic ox-mannosidase. This enzyme has been extensively characterized (Shoup and Touster, 1976; Bischoff and Kornfeld, 1986) . Because its cDNA predicts a 1 16-kDa protein that lacks both a transmembrane domain and a signal sequence, it may be involved in N-glycoprotein catabolism, rather than synthesis (Tulsiani et al., 1982; Bischoff et al., 1990) . Several unclassified a-mannosidases have been described and shown to share several characteristics with the ER/cytosolic enzyme. These involve rat brain, sperm, and liver microsomal a-1,2/1,3/1 ,6-mannosidases. These enzymes are not inhibited by swainsonine or dMNJ, although they differ with regard to precise substrate specificities. Their role in N-glycan processing remains elusive.
The branching of complex oligosaccharides occurs after the oligosaccharide is trimmed to GlcNAc2Man5 structure. The latter serves as a precursor to hybrid and complex N-glycans. In the medial Golgi compartment, GIcNAc-Tl transfers GIcNAc from UDP-GlcNAc to Man residue. GIcNAc-TI is the key enzyme in the biosynthesis of complex-type chains. Mutants lacking this enzyme accumulate the GlcNAc2Man5 structure, indicating that there are no compensatory activities for this transferase (Stanley and loffe, 1995) . Subsequently, Golgi cx-mannosidase 11 removes one a-1,3-and one a-1,6-linked mannose to yield GlcNAc2Man 3GlcNAc. Recent studies with a-mannosidase-II-deficient mice have uncovered an alternative pathway in N-glycoprotein biosynthesis, providing evidence that complex N-glycans can be produced via two distinct routes (Chui et al., 1997) . Although these mice exhibit defects in complex N-glycan synthesis in erythrocytes, none of the other cells and tissues examined is blocked in their production, necessitating the presence of a distinct a-mannosidase activity. This mannosidase activity, purified from Golgi and microsomal fractions and tentatively referred to as a-mannosidase III (Fig., C) , is specific for GlcNAc2Man5 and can generate GlcNAc2Man1 4 (Chui et al., 1997) . It is not clear whether this a-mannosidase is novel, or whether it is the ac-1,2/1,3/1,6-mannosidase previously described in the rat (Bonay and Hughes, 1991) . The fucosyltransferase that attaches fucose in the a-1,6-linkage to the asparaginebound GlcNAc in the core has a strict requirement for the prior action of the GlcNAc-TI. After the removal of the two a-mannose residues, the second GIcNAc is transferred from UDP-GlcNAc to the Man 1 > 6 arm by GlcNAcTll to create a bi-antennary structure. Another GlcNAcTlll transfers a GlcNAc to the central, core-bound mannose residue to yield a bisecting GlcNAc. The presence of the bisecting GlcNAc residue at the early stages of processing interferes with the removal of the a-mannose residues and the action of GIcNAc-TII and ox-1,6-fucosyltransferase, and leads to the formation of hybrid-type structures. The latter product can then be extended by the branching GlnNAc transferases to generate bi-, tri-, and tetra-antennary structures, which, in turn, can be terminated with different sugars that include Gal, GalNAc, GlcNAc, Fuc, and sialic acid residues, thus forming mature complex oligosaccharides (Fig., C, Table) . In general, a strict order of reactions in the synthesis of Nlinked glycans is observed. For instance, in the biosynthesis of ABH and Lewis blood groups, the A-genedependent GalNAc-T cannot attach GalNAc to a Gal residue unless this galactose is substituted by a fucose residue (Kuiijpers, 1993) .
Most of the strategies for isolating mutants in the synthesis of mature, N-linked glycan structures have been based on the use of toxic plant lectins (Stanley and loffe, 1995) . The rationale is based on the fact that lectinresistant cells do not bind the toxins, due to altered Nlinked carbohydrate expression on the cell surface. To date, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] enzymes in the Golgi part of the pathway have been either purified, or the genes encoding them cloned, as cDNAs or as genomic clones (Table) . Their functions are increasingly assessed by gene disruption and other transgenic approaches in mice. So far, GlcNAc-TI has been shown to be essential for morphogenesis, since embryos die early, with defects in neural tube formation, vascularization, and body plan symmetry (loffe and Metzler et al., 1994 ; see below). Moreover, transgenic mice overexpressing murine ac-1,3-galactosyltransferase had low body weight and died prematurely . In addition, increased expression of 3-1,4-galactosyltransferase resulted in attenuated binding between murine sperm and eggs (Youakim et al., 1994) . With the greater availability of transgenic mice exhibiting altered glycosylation, more functions relating to the specific expression of mature oligosaccharides will be revealed.
(iv) Golgi localization of glycosyltransferases and glycosidases There is a general notion that the glycosylation-processing enzymes are localized in the Golgi cisternae in the same sequence in which they act to modify oligosaccharide substrates. Therefore, a-mannosidases I and 11 have been thought to be in the cis and medial Golgi, the GlcNAc-TI in the medial Golgi, Gal-T in the trans-Golgi, and NANA-T in the trans-Golgi and trans-Golgi network. Recent (111) Regulation of N-glycosylation
The activity of a given N-glycoprotein represents a weighted average of its N-glycoforms, due to the diversity in either the types of carbohydrate moieties, the occupancy of glycosylation sequons, or both (Radamacher et al., 1988) . Terminal glycosylation sequences are differentially expressed in cells, and they are subject to changes during development, differentiation, and oncogenic transformation (Radamacher et al., 1988) . The latter appears to reflect modulation of gene expression on molecular rather than metabolic levels, since increasing evidence indicates that N-glycosylation genes are highly regulated with development, physiology, and environmental cues. The current understanding is that the extent of protein N-glycosylation and the sequences produced by a cell are determined by the level of expression, as well as the activity of the transferases that synthesize them. Although enormous progress in the purification of the component enzymes and the cloning of their corresponding genes has been made, insights into the regulation of protein N-glycosylation are limited. To date, most of the mechanistic information regarding the regulation of N-glycosylation on a molecular level comes from the studies of the dolichol pathway ALG genes in yeast.
(I) CONTROLS IN THE ER
The initial N-glycosylation events in the ER, or the level of the dolichol-linked oligosaccharide precursor, can affect N-glycoproteins via either modulation of the number of oligosaccharide motifs encoding physiologic information, regardless of protein backbone, or the activation of specific proteins requiring N-linked oligosaccharides. Here, the pools of dolichol phosphate for the synthesis of the dolichol-linked oligosaccharides, as well as other precursors for N-glycosylation, such as sugar nucleotides and dolichol phosphate-linked sugars, play important roles in the kinetics of the pathway (Kean, 1987) . In addition, glycosyltransferase and glycosidase activities are influenced by different cofactors. For instance, in yeast, the activity of the ALG7 gene product, GPT, is affected by phosphatidylinositol (PI) in vitro, while mammalian GPT is influenced by levels of Dol-P-Man and, to a lesser extent, Dol-P-glycerol, also in vitro (Kean, 1987 (Kukuruzinska and Lennon, 1994; Lennon et al., 1995) . Such selective regulation of ALG7 leads to changes in the extent of N-glycosylation (Orlean et al., 1983 (Orlean et al., , 1984 Pretel et al., 1995 (Lennon et al., 1997a) . To date, it is unclear whether expression of other N-glycosylation genes requires such a stringent, multilevel regulatory strategy. The yeast ALG7 promoter has multiple potential TATA boxes and GC-rich regions . On the other hand, consistent with housekeeping genes, the mammalian ALG7 promoter lacks a typical TATA box but is GC-rich, with several potential Sp-l binding sites, as well as CAAT and GATA boxes . The mouse promoter has been shown to have multiple transcription initiation sites spread over a large, 500-bp region, although no transcription initiation downstream from the first ATG has been reported . In contrast, the CHO ALG7 gene has multiple transcription initiation sites which have been shown to function in the synthesis of distinct GPT isoforms with different lengths of N-terminal regions in vitro (Huang et al., 1998) . Similar to ALG7, the promoters of the yeast ALG genes down-stream from ALG7 also have possible TATA boxes, as well as GC-rich regions. In yeast, several copies of the pheromone response element (PRE) , that functions in differentiation, are present in ALG7, ALG2, ALG6, and ALG5, and single copies are found in ALGI and ALG8. Moreover, cell-cycle regulatory boxes exist in the 5' noncoding regions of ALG7 and ALG5 . The mouse mammary ot-1,2-glucosidase I promoter has multiple transcription initiation sites. The promoter region of the cx-1,2-glucosidase gene lacks a TATA box but has several Sp-I binding sites, as well as other promoter elements such as those for Ap-2 and NF-KB (Khan etal, 1997) . Recent studies show that transcriptional regulation of ALG7 entails both repression and activation activities Lennon et a)., 1997a; Li and Vijay, 1997) . The mouse mammary ALG7 promoter functions in the negative regulation of this gene's expression in response to lactogenic hormones . In addition, the orphan receptor COUP-TF has been shown to activate ALG7 expression during mammary gland development (Li and Vi jay, 1997) . In yeast, indirect evidence, based on the kinetics of mRNA downregulation in the presence of protein synthesis inhibitors and mRNA degradation, suggests that changes in ALG7 transcript levels that accompany exit from the cell cycle also entail transcriptional repression (Kukuruzinska and Lennon, 1994; Lennon et a., 1997a ). The precise nature of the other ALG genes' regulatory elements remains obscure.
For the yeast ALG genes, post-transcriptional controls are likely to play a major role in their regulation. Several of the ALG genes give rise to complex transcription patterns-ALG7, ALG I, ALG6, ALG5, and WBP1-all of which produce two mRNAs (Lennon et a) ., 1995). In the case of ALG7 and ALGI genes, the heterogeneity resides in the 3 and 5' untranslated regions (UTRs), respectively (Kukuruzinska and Robbins, 1987; Albright and Robbins, 1990) . A feature shared by ALG7 from yeast and mammals is the complex transcriptional pattern. CHO ALG7 mRNAs are heterogeneous in size (Scocca and Krag, 1990; Zhu and Lehrman, 1990; Mota et al., 1994; ., 1998). In yeast, production of two classes of transcripts with different lengths of the 3' UTR has regulatory significance, since these transcripts have distinct halflives and translational competencies (Kukuruzinska and Lennon, 1994; Lennon et al., 1997a; Kukuruzinska and Hiltz, unpublished observations) . The sequences in the 3 UTR affect the efficiency of poly(A) site selection, and deletions in this region give rise to mutant phenotypes with lower GPT activity and hypersensitivity to tunicamycin . All of the yeast ALG genes studied to date produce unstable transcripts . This indicates that their degradation is either coupled to translation or is due to an unstable nuclease (Kukuruzinska and Lennon, 1994; Lennon et al., 1995 Lennon et al., , 1997a . SWPI, one of the OT subunit genes, produces a transcript that also decays rapidly, while WBPI, another essential OT subunit, gives rise to mRNAs with significantly longer half-lives. The ALG genes' mRNAs have AU-rich instability elements in their 3-UTRs. The decay kinetics of the early ALG gene transcripts are complex, while those of the late, including the OT subunit genes, follow simple, single-component decay patterns . The complex decay kinetics of some of the ALG genes may result from different compartmentalization of these mRNAs, reflecting additional levels of regulation. Furthermore, the short half-lives of the ALG genes' mRNAs are rapidly stabilized in the presence of protein synthesis inhibitors, such as cycloheximide (Kukuruzinska and Lennon, 1994; Lennon etal., 1995) .
The short half-lives of the ALG genes' mRNAs appear to play an important role in their regulation. Because of their intrinsic instability, even modest changes in mRNA turnover rates affect their steady-state levels over a brief period. Such a strategy allows for rapid changes in mRNA levels should the need arise. Studies with the yeast ts RNA polymerase II mutant cells (Nonet et cl., 1987) show that changes in ALG7 transcript decay rates serve a dual function: They can either directly determine the level of ALG7 mRNA or oppose regulatory changes at other control levels (Lennon et al., 1997a) . In response to environmental stresses, the abundance of ALG7 mRNA increases primarily via increased stability of its transcripts. In contrast, entry into the cell cycle, which is accompanied by a rapid induction of ALG7 mRNAs, and cell-cycle arrest, that involves downregulation of transcript abundance, are accompanied by inverse changes in transcript stabilities (Lennon et al., 1997a) . The opposing effects of transcript stabilities and abundance may reflect a failsafe control, consistent with the fact that inappropriate expression of ALG7 can interfere with cell functions . The ALG7 mRNAs, therefore, belong to a class of transcripts produced from genes whose decay rates are regulated when cells change their growth pattern or differentiate, such as proto-oncogenes, cell division, and heat-shock protein genes, as well as developmentally regulated genes (Peltz et al., 1991) .
Another important control for ALG7 involves the utilization of two clusters of poly(A) sites in the 3 UTR (Kukuruzinska and Robbins, 1987) . Removal of the sequences on the 3' side of the 1.4-and 1.6-kb poly(A) sites alters mRNA steady-state levels, indicating that they influence processing efficiency . The 1.4-kb mRNAs are less stable in vivo but more translationally competent in vitro compared with the 1.6-kb mRNAs (Kukuruzinska and Hiltz, unpub- respective poly(A) addition sites is biologically significant .
(2) CONTROLS IN THE GOLGI
The elaboration of N-linked oligosaccharide structures depends on the expression of Golgi-localized glycosyltransferases and glycosidases. Although it is generally presumed that glycosyltransferase expression is regulated at the level of transcription, little information exists regarding the molecular details of different regulatory mechanisms. Recent studies of the mouse GlcNAc-TI (MGAT1) gene have revealed multiple 5' exons that are differentially utilized by tissue-specific promoters (Yang et at., 1994) . The human GlcNAc-TI promoter also has multiple initiation sites involved in tissue-specific expression, but no TATA or CCAAT boxes (Yip et al., 1997) .
The human ot-mannosidase II and IIX promoters display multiple transcription initiation sites, and contain no TATA or CCAAT boxes. They have GC-rich regions near the start sites, with potential Sp-l binding elements (Ogawa et al., 1996) . Studies of the human placental GlcNAc-TIII (MGAT3) gene have uncovered homology in the 5' region to the promoter of murine 3-1,4-galactosyltransferase . Although no obvious TATA or CCAAT boxes are found in these sequences, cAMPresponsive (CRE) and insulin-responsive (IRE) elements, as well as potential Ap-2 and Sp-l sites, exist Koyama et al., 1996) . The human GlcNAc-TV gene (MGAT5) also has, in addition to potential Ap-l and Ap-2 binding sites, elements recognized by tissue-specific transcription factors . The gene encoding human 3-galactoside cx-2,6-sialyltransferase, a member of the NANA6-Gal family, produces transcripts with heterogeneity on the 5 ends; its promoter contains a TATA box, as well as several potential regulatory elements (Aas-Eng et al., 1995; Lo and Lau, 1996) . In contrast, the murine GalNAc cx-2,6-sialyltransferase gene, belonging to the NANA6-GalNAc family, does not contain either a TATA or CCAAT box in its promoter, although several GC-rich Sp-l and Ap-2 binding sites are present (Kurusawa et al., 1996) . A member of the NANA8-NANA family, murine cx-2,8-sialyltransferase produces multiple mRNAs that differ on the 3' ends and that can be detected in fetal and newborn brain and testes. The promoter regions of this sialyltransferase gene lack a typical TATA or CCAAT box (Yoshida et a!., 1996) .
As in the case of ALG7, transcript heterogeneity has been shown to be involved in the regulation of the bovine, Golgi -1,4-galactosyltransferase gene's expression. This gene uses alternative transcription initiation sites to specify two closely related proteins, with the long form containing an N-terminal extension of 13 amino acids (Russo et al., 1990 ). Both isoforms have been shown to be localized to the trans-Golgi and cell membrane, and their production to be regulated from distinct promoters in housekeeping and cell-specific fashions (Dennis et al., 1987) , and alterations in protein N-glycosylation patterns are consistent corollaries of developmental programs (Rademacher et al., 1988) . In addition, carbohydrate moieties of N-glycoproteins modulate a spectrum of developmentally relevant events (Rademacher et al., 1988 (Fukuda, 1992; Schachter and Brockhausen, 1992) . It first appears at the 8-cell stage and is essential for morula-stage embryo compaction (Bird and Kimber, 1984; Bayna et al., 1988) . The synthesis of SSEA-1 decreases at EIO, reaching very low levels by E15 (Muramatsu, 1992) . Complex N-linked glycans are also important during the post-implantation stage. Disruption of the mouse MGAT1 locus, encoding GlcNAc-TI, the Golgi glycosyltransferase (Kumar et al., 1990; Sakar et al., 1991; Pownall et al., 1992) that converts the processed high-mannose core into complex N-linked structures (Kornfeld and Kornfeld, 1985) , leads to embryonic death around day 10 (loffe Metzler et al., 1994) . Mutant embryos display defects in neither differentiation programs nor cytokine production, but in morphogenic processes of neural tube formation, vascularization, and the determination of leftright body plan asymmetry (loffe and Stanley, 1994; Metzler et al., 1994) . Thus, complex N-linked oligosaccharides are important for aspects of morphogenesis, but not for differentiation or cell viability (Stanley et al., 1975; Kumar and Stanley, 1985 
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Crit Rev Oral Biol Med 9(4):415-448 (1998) ALG7 expression and its effect on BEM I, which functions in the organization of the actin cytoskeleton . The phenotypes of alg7 mutants are strikingly similar to a temperature-sensitive (ts) calmodulin (cmdl) mutant that includes altered cell shape as well as cellcycle arrests (Ohya and Botstein, 1994; Ohya, personal communication) .
Increasing evidence suggests a role for N-glycosylation genes in growth and proliferation. The dolichol pathway ALG genes are becoming recognized as important for the correct execution of various aspects of the cell cycle, including cell-cycle arrest (reviewed by Kukuruzinska and Lennon, 1998) . In continuously cycling cells, ALG genes are expressed throughout the cell cycle, reaching peak values in the late S phase (Benton et al. 1996; Kukuruzinska and Bird, unpublished observations) . This may indicate a higher requirement for the early ALG genes' expression following DNA synthesis. Although the ALG genes belong to the class of housekeeping genes, expressed in all cells regardless of their proliferative state, they function in the primary genomic response to growth stimulation (Kukuruzinska and Lennon, 1994; Lennon et al., 1995; Pretel et al., 1995) , and several features of their expression resemble mammalian early growth response genes (Hofbauer and Denhardt, 1991) . In growth-arrested cells, the steady-state levels of the ALG mRNAs are significantly lower compared with proliferating cells, indicating that they are downregulated upon exit from the cell cycle (Kukuruzinska and Lennon, 1994; Lennon et al., 1995) . Studies of the kinetics of growth induction of ALG7 and other ALG genes mRNAs after stimulation of cells to re-enter the cell cycle show that transcripts are already detectable within 3 min Pretel et al., 1995) . The growth induction of the ALG genes occurs early in GI, because their mRNAs are upregulated to a similar extent in the presence of x-factor, an anti-mitogenic signal that causes growth arrest in late GI. In addition, ALG7 is induced in MDG3-GO-2 mutants, which are defective in their ability to re-enter the cell cycle from GO, although they display the initial response to mitogenic stimulation by upregulating the expression of early growth response genes (Drebot et al., 1987 (Drebot et al., , 1990 Pretel et al., 1995) . All of the ALG genes' transcripts are superinduced by cycloheximide following stimulation to proliferate, indicating that their mRNAs are upregulated in the absence of de novo protein synthesis (Kukuruzinska and Lennon, 1994; Lennon et al, 1995) . Hence, the ALG genes' transcripts display features of early growth-response gene mRNAs They are downregulated upon exit from the mitotic cycle into GO, they are rapidly induced following growth stimulation in the absence of de novo protein synthesis, and they have short half-lives that are stabilized by protein synthesis inhibitors (Hofbauer and Denhardt. 1991) .
The availability of yeast mutants in the early essential ALG genes has established functional relationships between these genes' expression and G1/S transition, progression through G2, and withdrawal from the cell cycle. Inhibition of the ALG7 protein product, GPT, with tunicamycin and mutations in either ALGI or ALG2 genes result in cell-cycle arrests (Arnold and Tanner, 1982; Klebl et al., 1984; Jackson et al., 1993) . Flow cytometric analysis of algl mutants shows that they arrest with a 1-N DNA content (Lennon et al., 1996) . In contrast, cells treated with tunicamycin have a 2-N DNA content. These cells have single nuclei, indicating that they arrest after DNA synthesis, but prior to nuclear division (Vai et al., 1987) . Because tunicamycin-treated cells are defective in bud emergence, but exhibit normal DNA synthesis, inhibition of ALG7 expression appears to perturb the vesicular traffic required for polarized growth and budding. The reason for the differences between algl and tunicamycin phenotypes is unclear, although they may reflect the different modes of perturbation of the ALG genes and their distinct consequences. Interestingly, alg7 mutants with a four-fold attenuated GPT activity are defective in bud site selection Lennon et al., 1997c) . The latter may reflect the effect of ALG7 on Bem Ip, which is thought to function in bud site selection and to associate with actin (Bardwell et al., 1994) . In addition, alg7 mutants are defective in GO arrest . Tunicamycin treatment also causes GI arrest in several mammalian cell lines (Ishii and Volpe, 1990; Langan and Slater, 1991; Larsson et al., 1993; Wejde et al., 1993) . Moreover, tunicamycin inhibits the proliferation of developing salivary cells, but not branching morphogenesis (Spooner et al., 1989) .
Asynchronous alg7 mutant cultures comprise a significant population of greatly enlarged cells compared with wild-type cells , suggesting that these cells acquire increased mass prior to division. These mutants have higher G2 DNA content than wild-type cells, although they do not contain an increased number of binucleate cells (Lennon et al., 1997b; Kukuruzinska and Lennon, unpublished observations) . The greater amount of G2 DNA in alg7 mutants is not due to differences in mitochondrial replication, since cells devoid of mitochondria, rhoO petites, display the same DNA profiles as wild-type cells (Lennon et al., 1996) . This suggests that alg7 mutants may be delayed in executing functions associated with G2/M progression, such as nuclear division. The phenotype of alg7 mutants is consistent with the effects of tunicamycin on yeast cells (Vai et al., 1987) .
In most eukaryotic systems, differentiation is accompanied by cell-cycle arrest (Gu et al., 1993; Lee et al., 1995 415-448 (1998) of only the first gene in the dolichol pathway, ALG7, although this does not appear to correlate with lower Nglycosylation (Orlean et al., 1983 (Orlean et al., , 1984 (Orlean et al., , 1985 . This suggests that selective inhibition of the first gene may be sufficient to regulate the dolichol pathway for the withdrawal from the cell cycle. In contrast to ALG7, transcripts of some of the ALG genes located downstream from it in the dolichol pathway are induced following growth arrest, suggesting a compensatory response to the downregulation of ALG7. Likewise, recovery from growth arrest correlates with a progressive increase in ALG7 expression.
Functional studies with alg7 mutants have begun to reveal the downstream targets of ALG7 required for cellcycle arrest. In contrast to wild-type cells, the steadystate levels of the ALG7 transcript, already attenuated in the alg7 mutant, are not downregulated upon GI arrest , suggesting that further downregulation of this gene may be deleterious to cell function. Yet, lack of ALG7 downregulation prevents a sustained cellcycle arrest in Gl (Lennon et al., 1997b) . Although in yeast, cell-cycle arrest occurs primarily via the downregulation of CLN 1 and CLN2 mRNAs (Valdevieso et al., 1993) , these transcripts persist in alg7 mutants. In fact, alg7 mutants never fully arrest in G1 and exhibit a noticeable G2 DNA peak at a time when wild-type cells arrest with a G I DNA content. Accordingly, alg7 mutants display a significantly increased population of cycling cells in the presence of an anti-mitogenic signal (Lennon et al., 1997b) . These data are consistent with ALG7 affecting CLN2 and ultimately CLN1 transcript levels via the positive feedback loop that requires a functional Cln2p/Cdc28p protein complex (Lennon et al., 1997b) . One possible downstream target of ALG7 may involve the negative regulator of Cln2p, Farlp (Valtz and Peter, 1997) , although other regulatory protein(s) that require N-glycosylation for optimal function and that may directly or indirectly affect cyclin expression may be involved. In any of these scenarios, underglycosylation of the target protein(s) would affect the downregulation of CLN expression, thus precluding a sustained cell-cycle arrest (Lennon et al., 1997b) .
Another early essential ALG gene, ALGI, has been linked to G1 cyclin expression and function (Benton et al., 1996) . Inviable alg1clnlcln2 mutants are rescued from lethality by overexpression of GC CLN genes. Moreover, mutations in ALGI, inviable in clnlcln2 background, are rescued from lethality by overexpression of CLN genes (Benton et al., 1996) . The N-glycosylation defect in algl cells is not corrected by the increased CLN expression, suggesting that the overexpression of cyclins allows progression through the cell cycle with diminished N-glycosylation. At this stage, the molecular basis of the ALGI and CLN relationship is unclear.
Most recently, a mammalian gene that functions in (Clark and Brugge, 1995 (Marrs et al., 1995) . Recent studies show that aberrant Nglycosylation of E-cadherin enhances cell-cell binding and suppresses metastasis (Yoshimura et al., 1996) .
(V) Pathologies Associated with N-glycosylation N-glycosylation represents a metabolic function that has been highly conserved in evolution. Recent information from the human genome project indicates that evolutionarily conserved genes are likely to cause disease when deregulated. Indeed, carbohydrate residues of gly-coproteins have been implicated in cancer, infectious diseases, and inflammation and thus are likely to be involved in the onset and progression of oral pathologies. Because N-glycans are expressed in a fairly specific manner on tumor cells and are important for the spread of malignancies, they have served in the development of anti-tumor vaccines and other clinical reagents. In addition, since specialized carbohydrate structures function in the initiation of pathogen-and toxin-mediated infections, vaccines targeted at inhibition of pathogen/toxin binding (as well as diagnostic reagents) are being developed. Moreover, acute inflammatory conditions are associated with various N-glycans that have been shown to be important in the initial attachment of white blood cells to endothelial surfaces, i.e., interactions between carbohydrates and receptor proteins, selectins (Varki, 1993) .
Several diseases have been correlated with deregulated expression of specific N-glycosylation genes. A lack of ox-mannosidase activity has even been observed in a variant of the human hereditary disease, HEMPAS, also called CDAII (congenital dyserythropoietic anemia type 11) , characterized by altered expression of one of several glycoprotein processing enzymes (Fukuda, 1990) . In one form of the disease, no cx-mannosidase 11 mRNA expression is detected. Lymphocyte cultures from the afflicted individuals have < 10% of the enzyme activity, while erythrocyte glycoproteins display mostly hybrid-type oligosaccharides, as predicted for this enzyme defect. Nonetheless, some patients have also been found to have low levels of GIcNAc-TII activity, and their red blood cells carry truncated N-linked glycans, consistent with low levels of this transferase. The latter is best explained by the existence of an alternative pathway for the synthesis of complex N-glycans. Accordingly, recent studies show that mice lacking atmannosidase 11 develop a dyserythropoietic anemia concurrent with loss of erythrocyte complex N-glycans, although these N-glycans are present in non-erythroid cells (Chui et al., 1997 Recently, a group of diseases likely to originate from defective N-glycosylation, the carbohydrate-deficient glycoprotein syndromes (CDGS), has been identified (laeken and Carchon, 1993) . Three types of the disorder have been described, depending on severity, although the systemic effects are serious in all cases. Type I arises from a defect in the transfer of oligosaccharide to AsnXaa-Ser/Thr sequons at sites that normally acquire the Nlinked glycans. Patients with this syndrome have underglycosylated serum glycoproteins, and the supposed defect lies in the dolichol-oligosaccharide biosynthesis (Powell et al., 1994) . Type 11 syndrome arises from an inherited deficiency of GlcNAc-TII (Jaeken and Carchon, 1993) , which has been correlated with a structural gene mutation in affected patients (Charuk et al., 1995; . This type of CDGS does not display the anemia symptoms of patients with CDAII, suggesting that there may be differential expressions of GIcNAc-TII in different cell types. The molecular basis of type III CDGS has not been elucidated.
In some cases, Glyc-T activity may contribute to disease fulmination (Varki, 1993) . For instance, the human stomach pathogen Heliobacter pylori binds to cells lining the stomach via an Lex-like (Leb) carbohydrate determinant (Falk et al., 1995) . Since individuals with the Lewisb blood group have increased incidence of gastric ulcers, and the Lewisb_negative phenotype is not deleterious, inhibition of x-1,3-Fuc-T involved in synthesizing this determinant may be a preventive measure against gastric ulcers.
Future studies are likely to establish direct linkage relationships between N-glycosylation deficiencies and oral dysfunctions. IgA, which serves as the first line of human defense at mucosal surfaces, requires N-glycosylation at the second domain of Ccx for interactions with its monocyte receptor (Carayannopoulos et al., 1994) . Moreover, the extensive N-glycosylation of IgA receptors on phagocytic cells at mucosal sites may be involved in the amplification of the protective role of IgA relevant to mucosal defense (Shen, 1992) . In addition, N-glycosylation confers stability on human lactoferrin, the latter being involved in host defense against infection and inflammation (van Berkel et al., 1995) . It has been suggested that the combined deficiency in secretory output of parotid lactoferrin and secretory IgA may contribute to the increased oral infections in HIV patients (Muller et al., 1992) ; it is possible that N-glycosylation also plays a role in determining the efficiency of the secretion of these important oral defense molecules. Furthermore, some of the salivary mucins that function in oral defense are, in addition to being 0-glycosylated, N-glycosylated, although the roles of their Nglycans remain unclear (Bobek et al., 1993; Denny et al., 1996; Nehrke and Tabak, 1997 ( 1998) important role in oral epithelial cell proliferation. Likewise, aberrant glycosylation detected in oral dysplastic leukoplakias and carcinomas may result from a lack of relevant, terminal N-glycan residues and may contribute to, or be a sole reason for, disordered proliferation. Furthermore, these changes in the expression of cell-surface carbohydrates have been recognized as useful for the histochemical evaluation of oral leukoplakias, papillomas, and carcinomas (Vigneswaran et al., 1990) . In addition, the expression of glycoconjugates on junctional epithelia has been proposed as a marker for periodontal disease (Mackenzie et al., 1995) .
Glycobiology in the Future
During the last decade, tremendous molecular and genetic advances have been made that allow for the identification of some of the biological roles of N-linked carbohydrates. Currently, with at least 60 glycosyltransferase and glycosidase genes cloned, the field is poised for the elucidation of the factors that regulate these genes and define their cell-and tissue-specific expression. Extensive progress in structural analyses of glycans through increased sensitivity of NMR and mass spectrometry continues to aid in the definition of N-linked carbohydrates present at the surfaces of specialized cells. Such knowledge will lead to the future alignment between aberrant expression of N-glycosylation genes and specific human diseases, including oral pathologies. And there are exciting prospects for the use of simple eukaryotes like yeast to elucidate the molecular mechanisms of human disease. Sequence comparisons between the human and the Saccharomyces cerevisiae genome databases increasingly reveal the presence of human disease gene homologues in yeast (Botstein et al., 1997) . At this stage, little is known about these genes except that their deregulation and inheritance cause diseases. The presence of good matches for human disease genes in yeast, such as TEL I for ataxia telangiectasia and SGS I for Werner's syndrome, opens up the possibility for an efficient characterization of protein linkages and mechanisms underlying specific disorders. In light of the fact that N-glycosylation is conserved in evolution, the likelihood of unraveling the molecular details of N-glycosylation-related dysfunctions is excellent. Furthermore, since increased sensitivity to antiviral agents frequently correlates with N-glycosylation status, further insights into the molecular aspects of protein Nglycosylation will prove useful in the discovery of new therapeutics. 
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